Replies to post #1833 on Ocera Therapeutics fka OCRX

[DewDiligence]

2015 cash-usage guidance is $28-32M.

[DewDiligence]

Cash guidance and clinical update:

http://finance.yahoo.com/news/ocera-reports-pipeline-progress-first-120500489.html

OCRX has enrolled “more than 70” patients in STOP-HE, which means that <160 patients (of the 230 in the upsized trial) are yet to be enrolled; guidance for completion of enrollment is 2H16.

Cash at 3/31/15 was $46.1M. Guidance for 2015 cash burn is $28-32M; since $5.1 was burned during 1Q15 (#msg-111643705), the guidance implies burn for the 9-month period from 4/1/15 to 12/31/15 of about $23-27M, and a 2015 year-end cash balance of $19-23M (assuming no financing and no new sources of revenue).